Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yury N Fedotov"'
Autor:
Dina V. Rebrova, Ilya Sablin, E A Fedorov, M S Isheyskaya, A N Bubnov, Irina V. Olovyanishnikova, Leonid M. Krasnov, Vladimir Rusakov, Ilya Sleptsov, Yury N. Fedotov, A A Uspenskaya, Roman Chernikov
Publikováno v:
Clinical and experimental thyroidology. 16:31-41
Thyrotropinoma is a rare pituitary tumor that causes the development of thyrotoxicosis syndrome as a result of hyperproduction of thyroid stimulating hormone (TSH). In the Russian literature over the past 10 years, one case of thyrotropinoma in a chi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0406cab1ffa525c4d3de406d491cf1e
https://doi.org/10.14341/ket12430
https://doi.org/10.14341/ket12430
Publikováno v:
Problems of Endocrinology. 66:104-112
BACKGROUND: Spontaneous recovery of the hypothalamic–pituitary–gonadal (HPG) axis after cessation of testosterone replacement therapy or after male contraception may take up to 24 months. There is insufficient data on the duration of recovery of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c7712db2a045d9f5c9d4f4aeffb678f
https://doi.org/10.14341/probl12223
https://doi.org/10.14341/probl12223
Autor:
Andrey E. Zdorov, Boris V. Afanasiev, Inna V. Vereschagina, Yury N. Fedotov, Oleg A. Rykavicin, Olga A. Malysheva, Yury L. Shevchenko, Tatiana I. Ionova, Anton V. Kishtovich, Andrei A. Novik, Alexey N. Kuznetcov, Alexandr A. Myasnikov, Gary I. Gorodokin, Roman Ivanov, Nikolay I. Baziy, Igor A. Lisukov, Denis A. Fedorenko, Andrey D. Kulagin, Sergey V. Shamanski, Vladimir Y. Melnichenko
Publikováno v:
Blood. 108:3072-3072
During the last decade HDCT+ASCT is more often used as a therapeutic option for MS patients. The major treatment outcomes for MS patients are disease-progressive free period and improvement of patient’s quality of life (QoL). We aimed to study trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a17da5256087bd6d3e8c766f892a2af2
https://doi.org/10.1182/blood.v108.11.3072.3072
https://doi.org/10.1182/blood.v108.11.3072.3072
Autor:
Yury L. Shevchenko, Inna V. Vereschagina, Vladimir Melnichenko, Andrei D. Kulagin, Gennady N. Bisaga, Gary I. Gorodokin, Boris V. Afanasiev, Yury N. Fedotov, Anton V. Kishtovich, Andrei A. Novik, Tatiana I. Ionova, Igor A. Lisukov, Denis A. Fedorenko, Olga A. Malysheva, Sergei Voloshin
Publikováno v:
Blood. 106:5467-5467
HDCT+ASCT is a new and promising therapy for MS patients. Among a number of unclear questions is the terms of conducting HDCT+ASCT. According to our concept there are 3 strategies of HDCT+ASCT depending on the terms of disease process: early, convent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fab88e1e5db1346fecf7e58e6055ed96
https://doi.org/10.1182/blood.v106.11.5467.5467
https://doi.org/10.1182/blood.v106.11.5467.5467
Autor:
Sergei Voloshin, Anton V. Kishtovich, Gennadi N. Bisaga, Andri A. Novik, Tatiana I. Ionova, Boris V. Afanasiev, Yury N. Fedotov, Olga A. Malysheva, Inna V. Vereschagina, Lubov V. Chelombit, Igor A. Lisukov, Denis A. Fedorenko, AD Kulagin, Yury L. Shevchenko, Vladimir Y. Melnichenko
Publikováno v:
Blood. 104:1875-1875
Objectives: HDCT+ASCT is a new and promising therapy for MS patients. Among a number of questions are the terms of conducting HDCT+ASCT. According to our concept there are 3 strategies of HDCT+ASCT depending on terms of disease stage: early, conventi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2dc3d0902c9a1dd4f70685a51190e0fd
https://doi.org/10.1182/blood.v104.11.1875.1875
https://doi.org/10.1182/blood.v104.11.1875.1875